In patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without significantly increasing the risk of stent thrombosis.
The video below demonstrates the mobile interface for the Intern Survival Guide. Covered is how to get to the website, how to navigate, how to search, and how to add a quick link for future use.